MARK LANDIS: Open Payments
NPI 1912128588 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,028 in 63 payments from 9 companies in 2025. Trend: 2023 $800 · 2024 $899 · 2025 $1,028
Food & beverage: $1,028
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 27 | $286 |
| BioCryst US Sales Co., LLC | 7 | $248 |
| ABBVIE INC. | 17 | $216 |
| CSL Behring | 3 | $92 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
| Incyte Corporation | 1 | $27 |
| GENZYME CORPORATION | 1 | $21 |
| Optinose US, Inc. | 1 | $16 |
Products named: NURTEC ODT, ORLADEYO, UBRELVY, Hizentra, QULIPTA, NEFFY, HYQVIA, OPZELURA.
Industry payments across DE — which companies pay providers there.
